Laboratory Corporation of America Holdings (NYSE:LH) insider F Samuel Eberts III sold 31,500 shares of the business’s stock in a transaction on Friday, August 25th. The shares were sold at an average price of $155.22, for a total transaction of $4,889,430.00. Following the sale, the insider now owns 31,894 shares of the company’s stock, valued at approximately $4,950,586.68. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Shares of Laboratory Corporation of America Holdings (NYSE LH) traded down 0.23% during trading on Tuesday, hitting $152.87. 544,447 shares of the company were exchanged. Laboratory Corporation of America Holdings has a 1-year low of $119.51 and a 1-year high of $164.22. The company has a 50 day moving average of $156.06 and a 200-day moving average of $145.76. The stock has a market capitalization of $15.56 billion, a PE ratio of 21.41 and a beta of 0.94.

Laboratory Corporation of America Holdings (NYSE:LH) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.40 by $0.07. The company had revenue of $2.50 billion for the quarter, compared to the consensus estimate of $2.47 billion. Laboratory Corporation of America Holdings had a return on equity of 16.85% and a net margin of 7.57%. Laboratory Corporation of America Holdings’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.36 earnings per share. On average, analysts forecast that Laboratory Corporation of America Holdings will post $9.51 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “F Samuel Eberts III Sells 31,500 Shares of Laboratory Corporation of America Holdings (LH) Stock” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/29/f-samuel-eberts-iii-sells-31500-shares-of-laboratory-corporation-of-america-holdings-lh-stock.html.

A number of equities analysts have issued reports on the stock. Craig Hallum reaffirmed a “buy” rating and set a $179.00 price objective (up from $157.00) on shares of Laboratory Corporation of America Holdings in a report on Thursday, July 27th. Credit Suisse Group reaffirmed a “buy” rating and set a $146.00 price objective on shares of Laboratory Corporation of America Holdings in a report on Sunday, May 28th. BidaskClub raised shares of Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating in a report on Saturday, June 17th. ValuEngine downgraded shares of Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a report on Saturday, June 3rd. Finally, Zacks Investment Research raised shares of Laboratory Corporation of America Holdings from a “sell” rating to a “hold” rating in a report on Thursday, July 27th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $159.75.

Institutional investors have recently modified their holdings of the company. CFO4Life Group LLC acquired a new position in shares of Laboratory Corporation of America Holdings during the first quarter worth about $312,000. Oxford Asset Management increased its position in shares of Laboratory Corporation of America Holdings by 68.6% in the first quarter. Oxford Asset Management now owns 51,622 shares of the medical research company’s stock worth $7,406,000 after buying an additional 21,003 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its position in shares of Laboratory Corporation of America Holdings by 2.1% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 9,900 shares of the medical research company’s stock worth $1,420,000 after buying an additional 199 shares in the last quarter. Elkfork Partners LLC increased its position in shares of Laboratory Corporation of America Holdings by 2.4% in the first quarter. Elkfork Partners LLC now owns 12,936 shares of the medical research company’s stock worth $1,856,000 after buying an additional 308 shares in the last quarter. Finally, Toronto Dominion Bank increased its position in shares of Laboratory Corporation of America Holdings by 55.5% in the first quarter. Toronto Dominion Bank now owns 27,613 shares of the medical research company’s stock worth $3,961,000 after buying an additional 9,857 shares in the last quarter. Institutional investors own 93.19% of the company’s stock.

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Insider Buying and Selling by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.